- Home
- CELC vs GCMG Comparison
CELC vs GCMG Comparison
Compare CELC & GCMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- GCMG
- Stock Information
- Founded
- CELC 2011
- GCMG 1971
- Country
- CELC United States
- GCMG United States
- Employees
- CELC N/A
- GCMG N/A
- Industry
- CELC Medical Specialities
- GCMG Finance/Investors Services
- Sector
- CELC Health Care
- GCMG Finance
- Exchange
- CELC Nasdaq
- GCMG Nasdaq
- Market Cap
- CELC 594.7M
- GCMG 524.4M
- IPO Year
- CELC 2017
- GCMG N/A
- Fundamental
- Price
- CELC $12.66
- GCMG $11.68
- Analyst Decision
- CELC Strong Buy
- GCMG Hold
- Analyst Count
- CELC 6
- GCMG 5
- Target Price
- CELC $29.17
- GCMG $12.80
- AVG Volume (30 Days)
- CELC 257.7K
- GCMG 244.5K
- Earning Date
- CELC 11-14-2024
- GCMG 11-08-2024
- Dividend Yield
- CELC N/A
- GCMG 3.77%
- EPS Growth
- CELC N/A
- GCMG N/A
- EPS
- CELC N/A
- GCMG N/A
- Revenue
- CELC N/A
- GCMG $462,593,000.00
- Revenue This Year
- CELC N/A
- GCMG $15.24
- Revenue Next Year
- CELC N/A
- GCMG $13.65
- P/E Ratio
- CELC N/A
- GCMG $154.07
- Revenue Growth
- CELC N/A
- GCMG 8.20
- 52 Week Low
- CELC $11.51
- GCMG $8.04
- 52 Week High
- CELC $22.19
- GCMG $12.43
- Technical
- Relative Strength Index (RSI)
- CELC 28.22
- GCMG 51.57
- Support Level
- CELC $15.33
- GCMG $10.91
- Resistance Level
- CELC $16.14
- GCMG $12.43
- Average True Range (ATR)
- CELC 0.97
- GCMG 0.33
- MACD
- CELC -0.28
- GCMG -0.03
- Stochastic Oscillator
- CELC 22.85
- GCMG 50.66
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.